Market
Keros Therapeutics announce further TROPOS trial safety concerns by end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Keros Therapeutics official press releases or regulatory filings
Story
Keros Therapeutics Halts Dosing in Phase 2 PAH Trial Due to Safety Concerns
Dec 12, 2024, 12:02 PM
Keros Therapeutics Inc. (Nasdaq: KROS) has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms of its ongoing Phase 2 TROPOS trial due to safety concerns related to pericardial effusion adverse events. The trial, which evaluates cibotercept (KER-012) in combination with background therapy for patients with pulmonary arterial hypertension (PAH), remains fully enrolled. Dosing in the 1.5 mg/kg treatment arm continues following a risk and benefit assessment by the independent Data Monitoring Committee (DMC). The company has informed investigators and regulatory authorities, including the FDA, of this decision and plans to present topline data from all treatment arms in the second quarter of 2025. Shares of Keros Therapeutics plunged following the announcement.
View original story
Similar markets
Unsuccessful • 25%
Partially Successful • 25%
Not Announced • 25%
Successful • 25%
No • 50%
Yes • 50%
Positive results • 25%
Inconclusive results • 25%
Trial extended • 25%
Negative results • 25%
Failure in both endpoints • 25%
Success in both primary and secondary endpoints • 25%
Success in primary endpoint only • 25%
Success in secondary endpoint only • 25%
Yes • 50%
No • 50%
Positive efficacy, but safety concerns • 25%
Negative efficacy and safety concerns • 25%
Positive efficacy and safety results • 25%
Negative efficacy, but good safety • 25%
Rejected • 33%
Request for more data • 34%
Approved • 33%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Significant improvement • 25%
No significant survival improvement • 25%
Trial stopped early for safety concerns • 25%
Trial stopped early for efficacy • 25%
Significant survival improvement • 25%
Conditional approval • 25%
Phase III trial initiation • 25%
No progress • 25%
BLA submission • 25%